Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 27(2)2022 Jan 10.
Article in English | MEDLINE | ID: mdl-35056734

ABSTRACT

Meloxicam (MLX) is a non-steroidal anti-inflammatory drug used to treat rheumatoid arthritis and osteoarthritis. However, its poor water solubility limits the dissolution process and influences absorption. In order to solve this problem and improve its bioavailability, we prepared it in nanocrystals with three different particle sizes to improve solubility and compare the differences between various particle sizes. The nanocrystal particle sizes were studied through dynamic light scattering (DLS) and laser scattering (LS). Transmission electron microscopy (TEM) was used to characterize the morphology of nanocrystals. The sizes of meloxicam-nanocrystals-A (MLX-NCs-A), meloxicam-nanocrystals-B (MLX-NCs-B), and meloxicam-nanocrystals-C (MLX-NCs-C) were 3.262 ± 0.016 µm, 460.2 ± 9.5 nm, and 204.9 ± 2.8 nm, respectively. Molecular simulation was used to explore the distribution and interaction energy of MLX molecules and stabilizer molecules in water. The results of differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) proved that the crystalline state did not change in the preparation process. Transport studies of the Caco-2 cell model indicated that the cumulative degree of transport would increase as the particle size decreased. Additionally, plasma concentration-time curves showed that the AUC0-∞ of MLX-NCs-C were 3.58- and 2.92-fold greater than those of MLX-NCs-A and MLX-NCs-B, respectively. These results indicate that preparing MLX in nanocrystals can effectively improve the bioavailability, and the particle size of nanocrystals is an important factor in transmission and absorption.


Subject(s)
Meloxicam/chemistry , Meloxicam/pharmacokinetics , Nanoparticles/chemistry , Administration, Cutaneous , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Caco-2 Cells , Calorimetry, Differential Scanning , Drug Evaluation, Preclinical , Dynamic Light Scattering , Humans , Male , Meloxicam/administration & dosage , Microscopy, Electron, Transmission , Models, Molecular , Nanoparticles/administration & dosage , Particle Size , Rats, Sprague-Dawley , X-Ray Diffraction
2.
ISA Trans ; 100: 145-154, 2020 May.
Article in English | MEDLINE | ID: mdl-31882176

ABSTRACT

For linear time-invariant systems, this paper develops a new kind of adaptive Kalman filter to deal with Kalman filtering problems troubled by unknown/inaccurate process noise covariance. The limitation of Kalman filter is that its performance would deteriorate or even degrade if the accurate noise statistics could not be obtained in advance. To reduce or mitigate the negative influence caused by unknown/mismatched process noise covariance, this work elaborates a novel covariance control scheme in which the prior error covariance is recursively regulated with the proportional form of feedback information: the posterior sequence is first evaluated as online feedback to constitute a closed-loop structure for covariance propagation process, and then a proportional gain is employed to amplify the feedback term and fasten the converging of the estimated covariance parameter; note that, the new approach is relatively more independent of the parameter of process noise covariance and, therefore, the Kalman theory's rigorous dependency on accurate process noise covariance could be relaxed significantly. The mathematical properties and sub-optimality of the new covariance control scheme are discussed in detail as well as some practical considerations. The advantage of this newly developed method in filtering accuracy, adaptability and simplicity are illustrated with an object tracking scenario.

SELECTION OF CITATIONS
SEARCH DETAIL
...